GSK Aug 2024 36.000 put
| Previous close | 0.1600 |
| Open | 0.1600 |
| Bid | 0.1000 |
| Ask | 0.1500 |
| Strike | 36.00 |
| Expiry date | 2024-08-16 |
| Day's range | 0.1600 - 0.1600 |
| Contract range | N/A |
| Volume | |
| Open interest | 535 |
- Reuters
GlaxoSmithKline Pharma India posts higher Q4 adjusted profit on strong sales
Drugmaker GlaxoSmithKline Pharma India reported a 49% rise in fourth-quarter adjusted profit on Friday, as strong demand for its generic medicines offset the impact of the government's ongoing price curbs on its key drugs. Revenue from operations rose 18% to 9.30 billion rupees, led by a 12% growth in its generic medicines portfolio which the company attributed to key focus brands Augmentin, Ceftum and Calpol. Earnings at drugmakers like GlaxoSmithKline Pharma and Abbott India have been pressured as prices of some of their key drugs were capped under the Indian government's essential medicines list (NLEM) since September 2022.
Evening StandardFTSE 100 Live 17 May: LandSec shares fall on results, GSK in £1.25bn final Haleon stake sale
GSK and Land Securities are in the FTSE 100 spotlight after the drugs giant sold its final Haleon shares and the property firm posted results. The sale of GSK’s remaining 4% stake raised £1.25 billion, having held 13% following its 2022 demerger of the Panadol and Sensodyne business. Land Securities revealed a smaller full-year loss of £341 million amid “robust” rental growth across its estate.
Yahoo Finance UKTrending tickers: Tesla, Reddit, Walmart and GSK
The latest investor updates on stocks that are trending on Friday.
